AnaptysBio, Inc.
ANAB
$64.23
-$0.49-0.76%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 41.84% | 242.81% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 41.84% | 242.81% | |||
| Cost of Revenue | -18.62% | -16.97% | |||
| Gross Profit | 84.11% | 388.63% | |||
| SG&A Expenses | 54.66% | -3.77% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -0.64% | -14.08% | |||
| Operating Income | 92.78% | 232.61% | |||
| Income Before Tax | 228.82% | 139.16% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 228.29% | 139.12% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 228.29% | 139.12% | |||
| EBIT | 92.78% | 232.61% | |||
| EBITDA | 92.38% | 233.87% | |||
| EPS Basic | 228.80% | 140.50% | |||
| Normalized Basic EPS | 229.32% | 140.54% | |||
| EPS Diluted | 204.27% | 138.78% | |||
| Normalized Diluted EPS | 204.45% | 138.88% | |||
| Average Basic Shares Outstanding | -- | -3.39% | |||
| Average Diluted Shares Outstanding | 0.00% | 0.72% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||